Table 7. Univariate and multivariate analyses of overall survival in primary ER-positive tumors.
| Variable | Category | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | ||
| Age | < 50 vs. ≥ 50 | 1.575 | 0.728–3.408 | 0.249 | - | - | - |
| Initial T stage | T1 vs. T2–4 | 3.308 | 1.103–9.918 | 0.033 | 2.328 | 0.694–7.807 | 0.171 |
| Initial N stage | N0 vs. N1–3 | 2.737 | 0.940–7.967 | 0.065 | 2.233 | 0.738–6.753 | 0.155 |
| Initial M stage | M0 vs. M1 | 2.495 | 0.842–7.392 | 0.099 | 1.987 | 0.557–7.094 | 0.290 |
| No. of [M] sites | Single vs. Multiple | 3.742 | 1.405–9.967 | 0.008 | 2.566 | 0.919–7.168 | 0.072 |
| ER status [M] | Positive vs. Negative | 5.905 | 1.850–18.843 | 0.003 | 6.255 | 1.758–22.263 | 0.005 |
| PR status [M] | Positive vs. Negative | 1.255 | 0.572–2.757 | 0.571 | - | - | - |
| HER2 status [M] | Positive vs. Negative | 2.395 | 0.564–10.174 | 0.236 | - | - | - |
| Ki-67 index [M] | Low vs. High | 2.258 | 0.939–5.429 | 0.069 | 1.452 | 0.500–4.216 | 0.493 |
HR = hazard ratio; CI = confidence interval; [M] = metastatic; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.